Takeda Pharmaceutical Co Ltd

Change company Symbol lookup

Select an option...

TKPHF Takeda Pharmaceutical Co Ltd

QRTEA Qurate Retail Inc

SRRA Sierra Oncology Inc

ICPT Intercept Pharmaceuticals Inc

MO Altria Group Inc

AI C3.ai Inc

INUV Inuvo Inc

PZZA Papa John's International Inc

REVHU Revolution Healthcare Acquisition Corp

DORM Dorman Products Inc

Go

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS(R) (brentuximab vedotin) plus chemotherapy combination will be...(BusinessWire)

--- Highest Total Number of Approvals for Takeda in a Fiscal Year Across Japan (4 NMEs), China (3 NMEs), the U.S. (2 NMEs), and Europe (1 NME) --- Robust Free Cash Flow of JPY 943.7 Billion ($7.8B); Net Debt/Adjusted EBITDA of 2.8x (BusinessWire)

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases -- CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare...(Globe Newswire)

--a^' Vaccine Facility in Singen, Germany, Wins Pharma 4.0 Category for Applying Digital Technologies in Production Process --a^' Recognition Illustrates Takeda's Patient-Centricity Throughout its Manufacturing and Supply Processes (BusinessWire)

Takeda (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical...(BusinessWire)

--a^' Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies --a^' Takeda is manufacturing Nuvaxovid at its Hikari facility and will begin distribution in Japan as soon as...(BusinessWire)

Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO(R) (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and...(BusinessWire)

FinancialNewsMedia.com News Commentary - Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent that it interferes with a person's daily life and activities. These functions...(PR Newswire)

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") today provided an update on the status and announced the completion of the acquisition of its own shares, which has been carried out pursuant to the provision of its Articles of...(BusinessWire)

Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO(R) (lanadelumab) in patients 2 to <12 years of age is complete and has met its...(BusinessWire)

--a^' Winners' Discoveries Reveal the Power of the Gut Microbiome --a^' Recipients Receive Unrestricted $200,000 USD Award Takeda (TSE:4502/NYSE:TAK) and the New York Academy of Sciences today announced the winners of the fourth Innovators in...(BusinessWire)

--a^' Approval Based on Results of Global Phase 3 HELP Study(TM), Phase 3 HELP OLE and a Phase 3 Study in Japanese Patients Evaluating the Efficacy and Safety of TAKHZYRO(1) --a^' In a Japan-Specific Phase 3 Study, 41.7% of the Patients Did Not...(BusinessWire)

--a^' Interim Patient-Reported Outcomes Showed a Reduction of Monthly Attack Rates in New Users and Showed Sustained Angioedema Control in Established Users Over Twelve-Months Using the Angioedema Control Test (AECT)(1,2,3) (BusinessWire)